Brittany Matney
Payments from drug & device makers
Across 824 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- Harmony Biosciences LLC$1K
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $5K from 23 others
What the payments were for
- Food & beverage$13,97199%
- Education$2061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 100 | $1,845 |
| AbbVie | 117 | $1,766 |
| Alkermes, Inc. | 94 | $1,437 |
| Harmony Biosciences LLC | 83 | $1,404 |
| Vanda Pharmaceuticals Inc. | 55 | $1,301 |
| Teva Pharmaceuticals USA, Inc. | 72 | $1,219 |
| Otsuka America Pharmaceutical, Inc. | 54 | $1,022 |
| Neurocrine Biosciences, Inc. | 36 | $656 |
| Axsome Therapeutics, Inc. | 36 | $559 |
| E.r. Squibb & Sons, L.L.C. | 25 | $541 |
| Lundbeck LLC | 33 | $506 |
| Johnson & Johnson | 25 | $465 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $255 |
| Noven Therapeutics, LLC | 15 | $197 |
| Idorsia Pharmaceuticals US Inc | 15 | $187 |
| Bausch Health US, LLC | 10 | $165 |
| Almatica Pharma LLC | 7 | $136 |
| Neos Therapeutics, LP | 6 | $91 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Ironshore Pharmaceuticals Inc. | 3 | $52 |
| Eisai Inc. | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 5 | $45 |
| Biogen | 3 | $42 |
| Merck | 3 | $38 |
| Indivior Inc. | 2 | $31 |
| Neurelis, Inc. | 1 | $30 |
| Brainsway USA Inc | 1 | $18 |
| Livanova USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,178 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 34 | $57,577 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $38,221 |
| SpravatoEsketamine Hcl | 15 | $19,608 |
| Vilazodone Hcl | 39 | $6,137 |
| BelsomraSuvorexant | 11 | $4,377 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 70 | $2,539 |
| Quetiapine Fumarate | 94 | $1,504 |
| Clonazepam | 134 | $1,100 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $1,092 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,064 |
| Hydroxyzine Hcl | 20 | $1,022 |
| Aripiprazole | 27 | $914 |
| Bupropion XlBupropion Hcl | 31 | $883 |
| Trazodone Hcl | 87 | $606 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,766 | $57,57734 claims |
| Alkermes, Inc.Lybalvi | $1,437 | $38,22126 claims |
| Johnson & JohnsonSpravato | $465 | $19,60815 claims |
| MerckBelsomra | $38 | $4,37711 claims |
| Almatica Pharma LLCSertraline Hcl | $136 | $23431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.
Other family in Omaha
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Sara LegleiterOmaha$12K
- Jasper KaufmanOmaha$10K
- Stacy NiemiOmaha$10K
- Amy RuddickOmaha$10K
- Michaela AbbottOmaha$8K
- Margaret WallaceOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.